Mr. Martin Shkreli served as Chief Executive Officer & Chairman at KaloBios Pharmaceuticals. Shkreli is the Founder of Turing Pharmaceuticals and served as its Chief Executive Officer until his resignation from the position due charges of securities fraud in December, 2015. He was previously the Founder and CEO of Retrophin, Inc. (Nasdaq: RTRX), a biotechnology company that develops treatments for rare and catastrophic diseases. Prior to that, Mr. Shkreli was a Managing Member of MSMB Capital, a New York-based hedge-fund and private-equity firm focused on health care investments. Mr. Shkreli has spent his career in the hedge-fund industry, previously in roles with Intrepid Capital Management and Cramer Berkowitz & Co. Mr. Shkreli lives in New York City and received a BBA in Finance from Baruch College.